Listen to article
7:31Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Let’s be honest, we all love the drama of a breakthrough cure. The headlines scream about a new wonder drug that could vanquish some terrible disease, and we all imagine scientists in white coats having their eureka moment. It’s a great story. But as an investor, I’ve learned that the best stories don’t always make the best investments. The real, and often overlooked, opportunity isn't just in the drug itself. It’s in the far less glamorous, but frankly more critical, business of getting that drug from the vial into the patient.
Recently, the American regulators, the FDA, gave the green light for an at-home, injectable version of an Alzheimer's treatment. Now, on the surface, this might sound like a minor bit of administrative shuffling. But to me, it’s a seismic shift. For decades, the model has been simple: if you’re seriously ill, you trek to a hospital, sit in a sterile room, and let a professional administer your treatment. It’s expensive, inconvenient, and frankly, a bit miserable.
This approval signals that the powers that be are finally catching up with reality. They are acknowledging that with clever engineering, patients can manage complex treatments themselves. This isn’t just about making life easier for the patient. It’s about cold, hard economics. Keeping people out of hospitals saves the entire system a fortune, and it means more people are likely to stick to their treatment plans.
You might wonder, why don’t the pharmaceutical giants just do this themselves? They have research budgets bigger than the GDP of small countries, after all. The truth is, they’re often brilliant at the molecular biology but shockingly clumsy when it comes to the practical engineering. Developing a pill that can survive the acid bath of the human stomach or designing an autoinjector that a person with shaky hands can use is a completely different skill set.
This creates a fascinating dependency. The behemoths of the industry are increasingly reliant on smaller, specialist firms to solve this "last mile" problem. Think of companies pioneering robotic pills to replace injections or developing gene therapies that can be delivered with pinpoint accuracy. These specialists hold the keys to unlocking the full market potential of blockbuster drugs, making them incredibly attractive partners or acquisition targets.
I like to think of it like this. Big Pharma discovers a fantastic new source of clean water. That’s the drug. But it’s useless if you can’t get it to people’s homes. The drug delivery companies are the plumbers. They design and build the sophisticated pipes, taps, and filtration systems that make the water useful. Without them, the water stays in the reservoir.
The technology here is genuinely impressive. We’re talking about wearable devices that drip-feed medication over days, or oral delivery systems that protect fragile molecules on their journey through the body. The barriers to entry are high, requiring a mastery of materials science and pharmacology. For investors, this is good news. It means the companies that get it right can build a strong, defensible position.
Of course, this isn't a one-way bet. Investing in healthcare is always a high-stakes game. The path to regulatory approval is long, expensive, and littered with failures. A promising technology can fall at the final hurdle, and a lucrative partnership can evaporate overnight. Many of these companies are burning through cash and might not see significant revenue for years. You need a strong stomach and a healthy dose of patience.
Still, the direction of travel seems clear. Healthcare is moving out of the clinic and into the living room. The convergence of an ageing population, the rise of chronic diseases, and the economic pressure to find more efficient care models creates a powerful tailwind. The companies enabling this shift are, to my mind, sitting in a very interesting spot. It’s a complex field, which is why focused themes like the Injectable Drug Innovation Opportunities 2025 basket are gaining traction. They offer a way to explore this niche without having to become a biomedical engineer overnight.
View the full Basket:Injectable Drug Innovation Opportunities 2025
View the full Basket:Injectable Drug Innovation Opportunities 2025
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
